Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
These studies should also be extended to other nuclei throughout the neuraxis, including those in hypothalamic and mesolimbic reward areas
Patients and doctors have long been awaiting (new window) a generic version of the drug, which many Canadians use for Type 2 diabetes and weight loss
Frequently Asked Questions Can Food Poisoning Be Worse While On GLP-1 Medication
Which is better for research: localized or systemic injections for bicep tendonitis
Executive Vice President & President, Lilly Cardiometabolic Health, Eli Lilly and Company Why this matters 1 Triple agonist = next-gen metabolic therapy Mimics GLP-1, GIP, and glucagon multi-pathway metabolic control 2 Diabetes + obesity convergence Simultaneous A1C + weight control = major unmet need solved 3 Competitive landscape shift Raises the bar vs GLP-1 mono & dual incretin therapies 4 No plateau signal is critical Suggests longer-term sustained efficacy Safety profile (expected class effects) Nausea, diarrhea, vomiting (dose-escalation phase) Discontinuation rates relatively low (25%) My takeaway 1 Metabolic disease treatment is entering multi-hormone era 2 Obesity + diabetes becoming one therapeutic category 3 Efficacy approaching bariatric-level outcomes 4 Sets new benchmark for Novo Nordisk and competitors Bottom line: Retatrutide isnt just competing Its redefining how we treat metabolic disease at the systems level #Diabetes #Obesity #GLP1 #Biotech #ClinicalTrials #Pharma #Innovation To view or add a comment, sign in 2,695 followers
Understanding the correct unit of measurement matters for patient safety
US$ 25.83
US$ 22.83
US$ 24.62
US$ 23.21
US$ 29.15
US$ 28.87
US$ 26.56
US$ 26.40
US$ 23.70
US$ 28.20
US$ 24.15
US$ 20.51
